Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genmab AS's Beginning Cash Position for the quarter that ended in Jun. 2026 was €1,320 Mil.
Genmab AS's quarterly Beginning Cash Position
declined
from Dec. 2025 (€1,504 Mil) to Mar. 2026 (€1,483 Mil) and
declined
from Mar. 2026 (€1,483 Mil) to Jun. 2026 (€1,320 Mil).
Genmab AS's annual Beginning Cash Position
increased
from Dec. 2023 (€1,301 Mil) to Dec. 2024 (€2,105 Mil) but then
declined
from Dec. 2024 (€2,105 Mil) to Dec. 2025 (€1,179 Mil).
The historical data trend for Genmab AS's Beginning Cash Position can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Beginning Cash Position of €1,320 Mil mean?
Genmab AS (FRA:GE91) has a Beginning Cash Position of €1,320 Mil as of Jun. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Genmab AS and its competitors.
Is Genmab AS's Beginning Cash Position too high?
Genmab AS's current Beginning Cash Position is €1,320 Mil. Overall, Genmab AS has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Beginning Cash Position compare to VRTX and REGN?
Genmab AS's Beginning Cash Position of €1,320 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Genmab AS and its competitors. Genmab AS's current Beginning Cash Position is €1,320 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (FRA:GE91) is currently considered Modestly Undervalued. The stock's GF Value™ is €29.40, compared to a current price of €25.40 — trading 13.6% below its estimated fair value. The current Beginning Cash Position is €1,320 Mil. Genmab AS's overall GF Score™ is 95/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Genmab AS (FRA:GE91), the current Beginning Cash Position is €1,320 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genmab AS (FRA:GE91) Overvalued in 2026?
Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued.
The current stock price of €25.40 is trading 13.6% below its estimated GF Value™ of €29.40.
GuruFocus considers Genmab AS to be Modestly Undervalued.
Key valuation signals for FRA:GE91:
Beginning Cash Position: €1,320 Mil
GF Value™: €29.40 vs. price of €25.40 (13.6% below fair value)
No single metric tells the full story. See the FRA:GE91 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
95GF Score
Get the complete analysis for FRA:GE91
Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:GE91 has been successfully added to your 
